Regenxbio (NASDAQ:RGNX) Shares Down 5.2%

Regenxbio Inc (NASDAQ:RGNX)’s stock price was down 5.2% during mid-day trading on Friday . The company traded as low as $40.60 and last traded at $41.21, approximately 714,122 shares traded hands during mid-day trading. An increase of 29% from the average daily volume of 552,520 shares. The stock had previously closed at $43.45.

A number of research analysts have recently issued reports on RGNX shares. ValuEngine upgraded shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Raymond James initiated coverage on shares of Regenxbio in a research report on Thursday, June 13th. They issued an “outperform” rating for the company. TheStreet cut shares of Regenxbio from a “c” rating to a “d+” rating in a research report on Thursday, May 9th. Morgan Stanley set a $84.00 price objective on shares of Regenxbio and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, Zacks Investment Research upgraded shares of Regenxbio from a “sell” rating to a “hold” rating in a research report on Thursday, July 25th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Regenxbio has an average rating of “Buy” and an average price target of $81.41.

The stock has a 50-day moving average of $48.86. The company has a current ratio of 14.21, a quick ratio of 14.21 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.59 billion, a PE ratio of 17.32 and a beta of 0.71.

Regenxbio (NASDAQ:RGNX) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04). Regenxbio had a negative return on equity of 9.90% and a negative net margin of 41.99%. The business had revenue of $0.88 million for the quarter. Equities research analysts anticipate that Regenxbio Inc will post -2.4 earnings per share for the current fiscal year.

In other news, insider Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction on Friday, July 19th. The shares were sold at an average price of $49.49, for a total value of $742,350.00. Following the completion of the transaction, the insider now owns 261,000 shares of the company’s stock, valued at approximately $12,916,890. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Patrick J. Christmas sold 5,000 shares of the business’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $52.99, for a total transaction of $264,950.00. Following the completion of the transaction, the senior vice president now directly owns 8,006 shares of the company’s stock, valued at approximately $424,237.94. The disclosure for this sale can be found here. Insiders have sold a total of 73,000 shares of company stock valued at $3,590,400 in the last ninety days. Company insiders own 13.80% of the company’s stock.

Several hedge funds have recently made changes to their positions in RGNX. Mckinley Capital Management LLC Delaware grew its holdings in shares of Regenxbio by 51.8% in the 1st quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 303 shares during the period. Financial Gravity Wealth Inc. acquired a new position in shares of Regenxbio in the 1st quarter valued at $55,000. Berman Capital Advisors LLC boosted its stake in Regenxbio by 41.6% in the 2nd quarter. Berman Capital Advisors LLC now owns 1,133 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 333 shares during the period. NEXT Financial Group Inc acquired a new position in Regenxbio in the 2nd quarter worth $69,000. Finally, SG3 Management LLC acquired a new position in Regenxbio in the 1st quarter worth $115,000. 81.38% of the stock is owned by institutional investors.

About Regenxbio (NASDAQ:RGNX)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: How Do Mutual Funds Work?

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.